MBX Biosciences, Inc. - Common Stock (MBX)

CUSIP: 55287L101

Q1 2026 13F Holders as of 31 Mar 2026

Holder snapshot 7 signals
Share change
+3,931,276
Put/Call ratio
38%
SEC-reported price per share
$29.85
Number of holders
155
Value change
+$114,687,441
Number of buys
73
Open additional details 1 more signal available
Number of sells
65
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
47,785,109

Security key

55287L101

Report period

Q1 2026

Institutions

155

Top holders

10

Ownership snapshot

Top reported holders of MBX - MBX Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Frazier Life Sciences Pub...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G 3/4/5 13F Lead comparable stake: 12% 13D/G row: Frazier Life Sciences Public Fund, L.P. Showing 1-6 of 15 holder rows.

Quick read

Frazier Life Sciences Public Fund, L.P. leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Frazier Life Sciences Public Fund, L.P.'s linked filing trail.
Comparable ownership Top 5
Frazier Life Sciences Public Fund... 12%
New Enterprise Associates 17, L.P. 8.1%
ORBIMED ADVISORS LLC 7.7%
Deep Track Capital, LP 6.6%
Norwest Venture Partners XVI, LP 4.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Frazier Life Sciences Public Fund, L.P.
13D/G
Patrick J. Heron
12%
$72,562,680
5,224,095 shares
+$9,264,602 26 Sep 2025
New Enterprise Associates 17, L.P.
13D/G 3/4/5
Edward T. Mathers · 10%+ Owner
8.1%
$63,340,795
3,619,474 shares
$0 06 Nov 2025
ORBIMED ADVISORS LLC
13F 13D/G 3/4/5
Company · Director, 10%+ Owner
7.7%
from 13D/G
$124,116,303
3,935,203 shares
31 Dec 2025
Deep Track Capital, LP
13F 13D/G
Company
6.6%
from 13D/G
$102,498,377
3,249,790 shares
31 Dec 2025
Norwest Venture Partners XVI, LP
13D/G
Tiba Aynechi
4.8%
$29,738,337
2,140,989 shares
$0 26 Sep 2025
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
13D/G 3/4/5
10%+ Owner
4.5%
$35,304,395
2,017,394 shares
$0 30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
155
Shares
52,523,690
Rows available
155
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q1 2026 Across Filers

Q1 2026 holders
155
Q1 2026 holders
155
Holder diff
0
Investor Q1 2026 Shares Q1 2026 Shares Share Diff Share Chg % Q1 2026 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .